XYRA is focused on developing a new interface that integrates wearables with a novel antiarrhythmic treatment aimed at enhancing the management of Atrial Fibrillation (AF). AF is a prevalent condition affecting approximately 44 million individuals globally, leading to significant health risks such as stroke, heart failure, and other complications. The company recognizes the limitations of traditional management strategies that primarily emphasize ventricular rate control and is committed to advancing therapies that aim to restore and maintain normal sinus rhythm, thereby improving patient outcomes.

The company’s approach addresses the high unmet need for safe and effective antiarrhythmic drugs that can reduce the frequency and duration of AF episodes. Long episodes of AF are particularly concerning, as they significantly increase the risk of stroke and hospitalization. By leveraging innovative technologies, XYRA aims to provide solutions that not only enhance the monitoring of AF through wearables but also improve therapeutic interventions, ultimately leading to better management of this complex arrhythmia.

United States

A new interface between wearables and a novel antiarrhythmic for improved AF management

XYRA

Company Details